Asia Pacific Sjs Ten Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
 예측 기간 |
2023 –2030 |
 시장 규모(기준 연도) |
USD 2,741.31 Million |
 시장 규모(예측 연도) |
USD 5,257.31 Million |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
>아시아 태평양 SJS/TEN 치료 시장, 치료(약물, 지원 치료, 입원, 격리, 연고 및 기타), 진단(신체 검사, 피부 생검 , 병력, 혈액 검사, 배양 및 기타), 원인(특정 치료, 감염 및 기타), 투여 경로(경구, 비경구, 국소 및 기타), 약물 유형(브랜드 및 제네릭), 치료 영역(병용 요법 및 단일 요법), 환자 유형(노인, 성인 및 소아), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터, 재택 치료 시설 및 기타), 유통 채널(소매 약국, 직접 입찰 및 기타) - 업계 동향 및 2030년까지의 예측.
아시아 태평양 SJS/TEN 치료 시장 분석 및 통찰력
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 이러한 질병이 드물기 때문에 치료 시장이 비교적 작습니다.
아시아 태평양 SJS/TEN 치료 시장은 약물이 주도하고 있으며, 약물은 이러한 질환의 주요 치료 형태입니다. 코르티코스테로이드, 정맥 면역글로불린(IVIG), 항생제는 SJS/TEN 치료에 가장 흔히 사용되는 약물입니다.
아시아 태평양 SJS/TEN 치료 시장은 2023년부터 2030년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2023년부터 2030년까지의 예측 기간 동안 8.6%의 CAGR로 성장하고 있으며 2022년 2,741.31백만 달러에서 2030년까지 5,257.31백만 달러에 도달할 것으로 분석합니다.
아시아 태평양 SJS/TEN 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 현지 시장 참여자의 영향, 새로운 수익 창출, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 당사에 문의하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다. 다양한 지역의 개발도상국에 있는 소매점의 확장성과 사업 확장, 기계 및 약물 제품의 안전한 유통을 위한 공급업체와의 파트너십은 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2023년부터 2030년까지 |
|
기준 연도 |
2022 |
|
역사적 연도 |
2021 (2015-2020까지 사용자 정의 가능) |
|
양적 단위 |
수익 (단위: USD 백만) |
|
다루는 세그먼트 |
치료(약물, 지원 치료, 입원, 격리, 연고 및 기타), 진단(신체 검사, 피부 생검, 병력, 혈액 검사, 배양 및 기타), 원인(특정 치료, 감염 및 기타), 투여 경로(경구, 비경구, 국소 및 기타), 약물 유형(브랜드 및 제네릭), 치료 영역(복합 치료 및 단일 치료), 환자 유형(노인, 성인 및 소아), 최종 사용자(병원, 전문 클리닉, 외래 수술 센터, 홈 케어 환경 및 기타), 유통 채널(소매 약국, 직접 입찰 및 기타) |
|
적용 국가 |
중국, 일본, 인도, 뉴질랜드, 호주, 한국, 인도네시아, 필리핀, 태국, 말레이시아, 싱가포르, 베트남, 대만, 기타 아시아 태평양 지역 |
|
시장 참여자 포함 |
3M(미국), Cardinal Health(미국), BD(미국), Smith + Nephew(영국), Novartis AG(스위스), Amneal Pharmaceuticals LLC.(미국), Amgen Inc.(미국), Pfizer Inc.(미국), Colgate-Palmolive Company(미국), Merck & Co., Inc.(미국), Mölnlycke Health Care AB.(스웨덴), Xttrium Laboratories(미국), Schülke & Mayr GmbH(독일), ICPA Health Products Ltd(인도), Purdue Pharma LP(미국), eugia(Aurobindo Pharma 자회사), AdvaCare Pharma(미국) 등 |
시장 정의
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 드물지만 생명을 위협하는 피부 질환으로, 일반적으로 심각한 약물 반응으로 인해 발생합니다. 이러한 질환은 피부의 최상층이 아래층과 분리되어 신체 대부분을 덮을 수 있는 고통스러운 물집과 궤양을 유발합니다. SJS는 피부의 작은 부분에 영향을 미치는 반면, TEN은 피부의 더 큰 부분에 영향을 미칩니다.
아시아 태평양 SJS/TEN 치료 시장의 정의는 이러한 질환을 관리하고 치료하도록 설계된 제품과 서비스를 말합니다. 시장에는 SJS/TEN 증상을 완화하고 환자의 삶의 질을 개선하는 데 도움이 되는 약물, 요법 및 기타 치료법이 있습니다. SJS/TEN 치료를 위한 약물 시장에는 증상을 완화하고 근본 원인을 치료하는 데 사용되는 여러 약물이 포함됩니다.
아시아 태평양 SJS/TEN 치료 시장 동향
이 섹션에서는 시장 동인, 이점, 제약 및 과제를 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전자
-
SJS/TEN의 유병률 및 발생률 증가
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 피부와 점막을 포함하는 심각하고 생명을 위협할 수 있는 질환입니다. SJS와 TEN은 질병 스펙트럼의 두 끝으로 간주되며, SJS는 더 가벼운 형태이고 TEN은 더 심각한 형태입니다. 이러한 질환의 특징은 강한 면역 반응으로 인해 표피(피부의 바깥층)와 진피(피부 아래의 층)가 분리되는 것입니다.
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 표피와 진피가 분리되는 것을 특징으로 하는 드물지만 심각한 피부 질환입니다. SJS/TEN의 발생률은 연간 100만 명당 약 1명으로 보고되었습니다. 그러나 최근 몇 년 동안 SJS/TEN의 발생률과 유병률에 대한 우려가 증가하고 있습니다.
-
SJS/TEN 치료를 위한 약물 개발의 진전
스티븐스-존슨 증후군(SJS)과 독성 표피괴사증(TEN)은 심각하고 잠재적으로 생명을 위협하는 질환으로 신속하고 적극적인 치료가 필요합니다. 현재 SJS/TEN을 치료할 수 있는 특정 약물이나 치료법은 없지만 약물 개발의 발전으로 인해 영향을 받는 환자에게 더 나은 치료 전략과 치료 결과가 나왔습니다. 그러나 SJS/TEN 치료를 위한 약물 개발을 위한 다양한 임상 시험이 진행 중입니다.
제지
-
SJS/TEN 치료와 관련된 높은 비용
SJS/TEN 치료가 비싼 주된 이유 중 하나는 집중적이고 장기적인 치료가 필요하기 때문입니다. SJS/TEN 환자는 종종 전문 화상 치료실에 입원해야 하며, 피부과 의사, 안과 의사, 중환자 치료 전문의를 포함한 의료진 팀으로부터 24시간 치료를 받습니다. 입원은 몇 주, 심한 경우 몇 달까지 지속될 수 있습니다. 이로 인해 병원 비용이 많이 들고 교통비, 숙박비, 식사비와 같은 관련 비용이 발생할 수 있습니다.
기회
-
SJS/TEN에 대한 효과적이고 안전한 치료법 개발
줄기세포 이식은 손상된 피부와 점막을 건강한 조직으로 대체하는 것을 목표로 하는 새로운 접근 방식입니다. 줄기세포를 환자의 피부에서 채취하여 배양한 후 손상된 부위에 다시 이식하는 자가 줄기세포 이식은 소규모 연구에서 유망한 결과를 보였습니다.
도전
- SJS/TEN 치료 승인에 대한 엄격한 정부 규정
SJS/TEN 치료 승인에 대한 엄격한 정부 규정은 제약 회사와 그들의 약물이 미국 식품의약국(FDA)이나 유럽 의약품 기관(EMA)과 같은 규제 기관으로부터 SJS/TEN 치료에 대한 승인을 받기 위해 거쳐야 하는 복잡하고 힘든 절차와 관련이 있습니다.
새로운 약물의 승인 절차에는 일반적으로 약물의 안전성과 효능을 평가하기 위한 인간을 대상으로 한 여러 단계의 임상 시험이 포함됩니다.
최근 개발 사항
- 2020년 6월, 아시아 태평양의 선도적 의료 기술 기업인 BD는 비상장 기업인 Straub Medical AG의 인수를 완료했다고 발표했습니다. 이 인수를 통해 회사는 Straub Medical AG의 귀중한 전문 지식과 경험을 추가하고 제품 포트폴리오를 확장했습니다. 이를 통해 회사는 시장에서 확장하고 성장할 수 있습니다.
- 2019년 1월, Mölnlycke Health Care AB는 상처 치료 역량을 더욱 강화하기 위해 MandJ Airlaid Products A/S를 인수합니다. 인수와 관련하여 MandJ와 그 직원은 Mölnlycke의 필수적인 부분이 될 것입니다. 이 인수는 Mölnlycke가 고급 상처 드레싱을 생산하는 데 필요한 에어 레이드 소재에 대한 공급을 확보하고 기존 및 미래 제품의 혁신과 제품 개발을 가속화하여 상처 치료 사업을 성장시키는 데 도움이 될 것입니다. 이를 통해 회사는 시장에서 확장하고 성장할 수 있습니다.
아시아 태평양 SJS/TEN 치료 시장 범위
아시아 태평양 SJS/TEN 치료 시장은 치료, 진단, 원인, 투여 경로, 약물 유형, 치료 유형, 환자 유형, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 분류됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
아시아 태평양 SJS/TEN 치료 시장은 치료, 진단, 원인, 투여 경로, 약물 유형, 치료 유형, 환자 유형, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 분류됩니다.
치료
- 약물
- 지원 케어
- 연고
- 입원
- 격리
- 기타
아시아 태평양 SJS/TEN 치료 시장은 치료를 기준으로 약물, 지원 치료, 입원, 격리, 연고 및 기타로 구분됩니다.
진단
- 신체 검사
- 병력
- 피부 생검
- 혈액 검사
- 문화
- 기타
아시아 태평양 SJS/TEN 치료 시장은 진단을 기준으로 신체 검사, 피부 생검, 병력, 혈액 검사, 배양 및 기타로 구분됩니다.
원인
- 특정 치료
- 전염병
- 기타
아시아 태평양 SJS/TEN 치료 시장은 원인을 기준으로 특정 치료, 감염 및 기타로 구분됩니다.
투여 경로
- 경구
- 비경구적
- 뉴스 영화
- 기타
투여 경로를 기준으로 아시아 태평양 SJS/TEN 치료 시장은 경구, 비경구, 국소 및 기타로 구분됩니다.
약물 유형
- 브랜드화
- 일반적인
아시아 태평양 SJS/TEN 치료 시장은 약물 유형을 기준으로 브랜드 제품과 제네릭 제품으로 구분됩니다.
치료 유형
- 단일요법
- 복합치료
치료 유형을 기준으로 아시아 태평양 SJS/TEN 치료 시장은 복합 치료와 단일 치료로 구분됩니다.
환자 유형
- 소아과
- 성인
- 노인
환자 유형을 기준으로 아시아 태평양 SJS/TEN 치료 시장은 노인, 성인, 소아로 구분됩니다.
최종 사용자
- 병원
- 전문 클리닉
- 외래 수술 센터
- 홈케어 세팅
- 기타
아시아 태평양 SJS/TEN 치료 시장은 최종 사용자를 기준으로 병원, 전문 클리닉, 외래 수술 센터, 가정 치료 시설 및 기타로 구분됩니다.
유통 채널
- 직접 입찰
- 소매 약국
- 기타
아시아 태평양 SJS/TEN 치료 시장은 유통 채널을 기준으로 소매 약국, 직접 입찰 및 기타로 구분됩니다.
아시아 태평양 SJS/TEN 치료 시장 지역 분석/통찰력
아시아 태평양 SJS/TEN 치료 시장은 치료, 진단, 원인, 투여 경로, 약물 유형, 치료 유형, 환자 유형, 최종 사용자 및 유통 채널을 기준으로 9개의 주요 세그먼트로 분류됩니다.
이 시장 보고서에서 다루는 국가는 중국, 일본, 인도, 뉴질랜드, 호주, 한국, 인도네시아, 필리핀, 태국, 말레이시아, 싱가포르, 베트남, 대만, 그리고 기타 아시아 태평양 지역입니다.
중국은 R&D 투자 증가로 시장 성장을 촉진할 것으로 예상되어 시장을 주도할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 아시아 태평양 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 아시아 태평양 SJS/TEN 치료 시장 점유율 분석
아시아 태평양 SJS/TEN 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, R&D 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭 및 호흡, 응용 프로그램 우세, 기술 수명선 곡선이 포함됩니다. 위에 제공된 데이터 포인트는 아시아 태평양 SJS/TEN 치료 시장에 대한 회사의 초점과만 관련이 있습니다.
아시아 태평양 SJS/TEN 치료 시장에서 활동하는 주요 기업으로는 3M(미국), Cardinal Health(미국), BD(미국), Smith + Nephew(영국), Novartis AG(스위스), Amneal Pharmaceuticals LLC.(미국), Amgen Inc.(미국), Pfizer Inc.(미국), Colgate-Palmolive Company(미국), Merck & Co., Inc.(미국), Mölnlycke Health Care AB.(스웨덴), Xttrium Laboratories(미국), Schülke & Mayr GmbH(독일), ICPA Health Products Ltd(인도), Purdue Pharma LP(미국), eugia(Aurobindo Pharma의 자회사), AdvaCare Pharma(미국) 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC SJS/TEN TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 KEY TRENDS
4.2 COST OF TREATMENT
4.3 KEY PLAYERS STRATEGIES
4.4 LONG TERM GROWTH APPROACH
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DEMOGRAPHIC TRENDS
6.3 PATIENT FLOW DIAGRAM
6.4 KEY PRICING STRATEGIES
6.5 KEY PATIENT ENROLLMENT STRATEGIES
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN
7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT
7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN
7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT
7.2 RESTRAINTS
7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN
7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT
7.3 OPPORTUNITIES
7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN
7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT
7.4 CHALLENGES
7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN
7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT
8 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANTIHISTAMINES
8.2.1.1 HYDROXYZINE
8.2.1.2 FEXOFENADINE
8.2.2 CORTICOSTEROID
8.2.2.1 DEXAMETHASONE
8.2.2.2 PREDNISOLONE
8.2.2.3 METHYLPREDNISOLONE
8.2.2.4 HYDROCORTISONE
8.2.2.5 OTHERS
8.2.3 ANTIBIOTICS
8.2.3.1 NAFCILLIN
8.2.3.2 GENTAMICIN
8.2.3.3 OTHERS
8.2.4 ANALGESICS
8.2.4.1 MORPHINE
8.2.4.2 FENTANYL CITRATE
8.2.4.3 OTHERS
8.2.5 ANTICOAGULANTS
8.2.6 ANTISEPTICS
8.2.6.1 CHLORHEXIDINE GLUCONATE
8.2.6.1.1 PERIOGARD
8.2.6.1.2 PERIDEX
8.2.6.1.3 AVAGARD
8.2.6.1.4 HIBICLENS
8.2.6.1.5 OTHERS
8.2.6.2 OCTENISEPT
8.2.6.3 POLYHEXANIDE SOLUTIONS
8.2.6.4 OTHERS
8.2.7 INTRAVENOUS IMMUNOGLOBULIN
8.2.8 CYCLOSPORINE
8.2.8.1 NEORAL
8.2.8.2 SANDIMMUNE
8.2.8.3 OTHERS
8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)‒BLOCKING AGENT (ETANERCEPT)
8.2.10 OTHER TREATMENT
8.2.10.1 CYCLOPHOSPHAMIDE
8.2.10.2 N-ACETYLCYSTEINE
8.2.10.3 MONOCLONAL ANTIBODIES
8.2.10.4 THALIDOMIDE
8.3 SUPPORT CARE
8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES
8.3.2 PAIN MANAGEMENT
8.3.2.1 LIDOCAINE
8.3.2.2 OTHERS
8.3.3 NUTRITION SUPPORT
8.3.4 ORAL CARE
8.3.5 PLASMAPHERESIS
8.3.6 BANDAGES
8.3.6.1 BIOLOGICAL DRESSING
8.3.6.1.1 ALLOGRAFT
8.3.6.1.2 XENOGRAFT
8.3.6.1.3 HOMOGRAFT
8.3.6.1.4 OTHERS
8.3.6.2 BIOSYNTHETIC DRESSING
8.3.6.3 SILVER IMPREGNATED DRESSING
8.4 HOSPITALIZATION
8.5 ISOLATION
8.6 OINTMENTS
8.6.1 BENZOCAINE
8.6.2 AMERICAINE
8.6.3 ANBESOL
8.6.4 CHIGGEREX PLUS
8.6.5 OTHERS
8.7 OTHERS
9 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DIAGNOSIS
9.1 OVERVIEW
9.2 PHYSICAL EXAM
9.3 SKIN BIOPSY
9.4 MEDICAL HISTORY
9.5 BLOOD TEST
9.5.1 COMPLETE BLOOD COUNT
9.5.2 ERYTHROCYTE SEDIMENTATION RATE
9.5.3 COAGULATION STUDIES
9.5.4 UREA AND ELECTROLYTES
9.5.5 LIVER FUNCTION TEST
9.6 CULTURES
9.7 OTHERS
10 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE
10.1 OVERVIEW
10.2 SPECIFIC TREATMENT
10.3 INFECTION
10.4 OTHERS
11 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 SUBCUTANEOUS
11.3.3 OTHERS
11.4 TOPICAL
11.4.1 OINTMENTS
11.4.2 SOLUTION
11.4.3 CREAMS
11.4.4 OTHERS
11.5 OTHERS
12 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 BRANDED
12.2.1 NEORAL
12.2.2 SANDIMMUNE
12.2.3 VISTARIL
12.2.4 DURAMORPH
12.2.5 FENTORA
12.2.6 ENBREL
12.2.7 OTHERS
12.3 GENERIC
13 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY THERAPY TYPE
13.1 OVERVIEW
13.2 COMBINATION THERAPY
13.3 MONOTHERAPY
14 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY PATIENT TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.2.1 FEMALE
14.2.2 MALE
14.3 ADULT
14.3.1 FEMALE
14.3.2 MALE
14.4 PEDIATRIC
15 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTER
15.5 HOMECARE SETTING
15.6 OTHERS
16 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.2.1 HOSPITAL ASSOCIATED PHARMACIES
16.2.2 DRUG STORE
16.2.3 ONLINE PHARMACIES
16.3 DIRECT TENDERS
16.4 OTHERS
17 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY REGION
17.1 ASIA-PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 SOUTH KOREA
17.1.5 AUSTRALIA
17.1.6 SINGAPORE
17.1.7 THAILAND
17.1.8 INDONESIA
17.1.9 PHILIPPINES
17.1.10 MALAYSIA
17.1.11 NEW ZEALAND
17.1.12 VIETNAM
17.1.13 TAIWAN
17.1.14 REST OF ASIA-PACIFIC
18 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 PFIZER INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 NOVARTIS AG
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 MERCK & CO., INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 AMNEAL PHARMACEUTICAL LLC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 AMGEN INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 ADVACARE PHARMA
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.7 BD
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 CARDINAL HEALTH
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 COLGATE-PALMOLIVE COMPANY
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENT
20.1 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA)
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ICPA HEALTH PRODUCTS LTD
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 3M
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENT
20.13 MOLNLYCKE HEALTH CARE AB.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 PURDUE PHARMA L.P.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 SCHULKE & MAYR GMBH
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 SMITH + NEPHEW
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 XTTRIUM LABORATORIES
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, PATENT ANALYSIS
TABLE 2 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 3 ASIA-PACIFIC MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 ASIA-PACIFIC MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 5 ASIA-PACIFIC ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 6 ASIA-PACIFIC CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 7 ASIA-PACIFIC ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 8 ASIA-PACIFIC ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 9 ASIA-PACIFIC ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 10 ASIA-PACIFIC CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 11 ASIA-PACIFIC CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 12 ASIA-PACIFIC OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 13 ASIA-PACIFIC SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 ASIA-PACIFIC SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 15 ASIA-PACIFIC PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 16 ASIA-PACIFIC BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 17 ASIA-PACIFIC BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 18 ASIA-PACIFIC HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 ASIA-PACIFIC ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 ASIA-PACIFIC OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 ASIA-PACIFIC OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 22 ASIA-PACIFIC OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 24 ASIA-PACIFIC PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 ASIA-PACIFIC SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 ASIA-PACIFIC MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 ASIA-PACIFIC BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 ASIA-PACIFIC BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 32 ASIA-PACIFIC SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 ASIA-PACIFIC INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 ASIA-PACIFIC OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 36 ASIA-PACIFIC ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 ASIA-PACIFIC PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 ASIA-PACIFIC PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 39 ASIA-PACIFIC TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 ASIA-PACIFIC TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 41 ASIA-PACIFIC OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 43 ASIA-PACIFIC BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 ASIA-PACIFIC BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 45 ASIA-PACIFIC GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 47 ASIA-PACIFIC COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 ASIA-PACIFIC GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 52 ASIA-PACIFIC ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 ASIA-PACIFIC ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 54 ASIA-PACIFIC PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 56 ASIA-PACIFIC HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 ASIA-PACIFIC SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 ASIA-PACIFIC AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 ASIA-PACIFIC HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 ASIA-PACIFIC OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 62 ASIA-PACIFIC RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 ASIA-PACIFIC RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 64 ASIA-PACIFIC DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 ASIA-PACIFIC OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 67 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 68 ASIA-PACIFIC MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 69 ASIA-PACIFIC ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 70 ASIA-PACIFIC CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 71 ASIA-PACIFIC ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 72 ASIA-PACIFIC ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 73 ASIA-PACIFIC ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 74 ASIA-PACIFIC CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 75 ASIA-PACIFIC CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 76 ASIA-PACIFIC OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 77 ASIA-PACIFIC SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 78 ASIA-PACIFIC PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 79 ASIA-PACIFIC BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 80 ASIA-PACIFIC BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 81 ASIA-PACIFIC OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 82 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 83 ASIA-PACIFIC BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 84 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 85 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 86 ASIA-PACIFIC PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 87 ASIA-PACIFIC TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 88 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 ASIA-PACIFIC BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 90 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 91 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 92 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 93 ASIA-PACIFIC ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 94 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 96 ASIA-PACIFIC RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 97 CHINA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 98 CHINA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 99 CHINA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 100 CHINA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 101 CHINA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 102 CHINA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 103 CHINA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 104 CHINA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 105 CHINA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 106 CHINA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 107 CHINA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 108 CHINA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 109 CHINA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 110 CHINA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 111 CHINA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 112 CHINA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 113 CHINA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 114 CHINA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 115 CHINA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 116 CHINA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 117 CHINA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 118 CHINA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 119 CHINA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 120 CHINA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 121 CHINA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 122 CHINA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 123 CHINA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 124 CHINA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 125 CHINA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 126 CHINA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 JAPAN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 128 JAPAN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 129 JAPAN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 130 JAPAN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 131 JAPAN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 132 JAPAN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 133 JAPAN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 134 JAPAN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 135 JAPAN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 136 JAPAN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 137 JAPAN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 138 JAPAN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 139 JAPAN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 140 JAPAN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 141 JAPAN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 142 JAPAN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 143 JAPAN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 144 JAPAN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 145 JAPAN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 146 JAPAN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 JAPAN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 148 JAPAN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 149 JAPAN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 150 JAPAN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 151 JAPAN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 152 JAPAN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 153 JAPAN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 154 JAPAN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 JAPAN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 JAPAN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 157 INDIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 158 INDIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 159 INDIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 160 INDIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 161 INDIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 162 INDIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 163 INDIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 164 INDIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 165 INDIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 166 INDIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 167 INDIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 168 INDIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 169 INDIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 170 INDIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 171 INDIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 172 INDIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 173 INDIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 174 INDIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 175 INDIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 176 INDIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 177 INDIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 178 INDIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 179 INDIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 180 INDIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 181 INDIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 182 INDIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 183 INDIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 184 INDIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 185 INDIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 186 INDIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 187 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 188 SOUTH KOREA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 189 SOUTH KOREA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 190 SOUTH KOREA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 191 SOUTH KOREA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 192 SOUTH KOREA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 193 SOUTH KOREA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 194 SOUTH KOREA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 195 SOUTH KOREA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 196 SOUTH KOREA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 197 SOUTH KOREA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 198 SOUTH KOREA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 199 SOUTH KOREA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 200 SOUTH KOREA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 201 SOUTH KOREA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 202 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 203 SOUTH KOREA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 204 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 205 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 206 SOUTH KOREA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 207 SOUTH KOREA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 208 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 209 SOUTH KOREA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 210 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 211 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 212 SOUTH KOREA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 213 SOUTH KOREA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 214 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 215 SOUTH KOREA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 216 SOUTH KOREA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 217 AUSTRALIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 218 AUSTRALIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 219 AUSTRALIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 220 AUSTRALIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 221 AUSTRALIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 222 AUSTRALIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 223 AUSTRALIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 224 AUSTRALIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 225 AUSTRALIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 226 AUSTRALIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 227 AUSTRALIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 228 AUSTRALIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 229 AUSTRALIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 230 AUSTRALIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 231 AUSTRALIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 232 AUSTRALIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 233 AUSTRALIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 234 AUSTRALIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 235 AUSTRALIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 236 AUSTRALIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 237 AUSTRALIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 238 AUSTRALIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 239 AUSTRALIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 240 AUSTRALIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 241 AUSTRALIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 242 AUSTRALIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 243 AUSTRALIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 244 AUSTRALIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 245 AUSTRALIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 246 AUSTRALIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 247 SINGAPORE SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 248 SINGAPORE MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 249 SINGAPORE ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 250 SINGAPORE CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 251 SINGAPORE ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 252 SINGAPORE ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 253 SINGAPORE ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 254 SINGAPORE CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 255 SINGAPORE CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 256 SINGAPORE OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 257 SINGAPORE SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 258 SINGAPORE PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 259 SINGAPORE BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 260 SINGAPORE BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 261 SINGAPORE OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 262 SINGAPORE SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 263 SINGAPORE BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 264 SINGAPORE SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 265 SINGAPORE SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 266 SINGAPORE PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 267 SINGAPORE TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 268 SINGAPORE SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 269 SINGAPORE BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 270 SINGAPORE SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 271 SINGAPORE SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 272 SINGAPORE GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 273 SINGAPORE ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 274 SINGAPORE SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 275 SINGAPORE SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 276 SINGAPORE RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 277 THAILAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 278 THAILAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 279 THAILAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 280 THAILAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 281 THAILAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 282 THAILAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 283 THAILAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 284 THAILAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 285 THAILAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 286 THAILAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 287 THAILAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 288 THAILAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 289 THAILAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 290 THAILAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 291 THAILAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 292 THAILAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 293 THAILAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 294 THAILAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 295 THAILAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 296 THAILAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 297 THAILAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 298 THAILAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 299 THAILAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 300 THAILAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 301 THAILAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 302 THAILAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 303 THAILAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 304 THAILAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 305 THAILAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 306 THAILAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 307 INDONESIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 308 INDONESIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 309 INDONESIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 310 INDONESIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 311 INDONESIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 312 INDONESIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 313 INDONESIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 314 INDONESIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 315 INDONESIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 316 INDONESIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 317 INDONESIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 318 INDONESIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 319 INDONESIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 320 INDONESIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 321 INDONESIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 322 INDONESIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 323 INDONESIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 324 INDONESIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 325 INDONESIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 326 INDONESIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 327 INDONESIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 328 INDONESIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 329 INDONESIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 330 INDONESIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 331 INDONESIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 332 INDONESIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 333 INDONESIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 334 INDONESIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 335 INDONESIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 336 INDONESIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 337 PHILIPPINES SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 338 PHILIPPINES MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 339 PHILIPPINES ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 340 PHILIPPINES CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 341 PHILIPPINES ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 342 PHILIPPINES ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 343 PHILIPPINES ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 344 PHILIPPINES CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 345 PHILIPPINES CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 346 PHILIPPINES OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 347 PHILIPPINES SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 348 PHILIPPINES PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 349 PHILIPPINES BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 350 PHILIPPINES BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 351 PHILIPPINES OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 352 PHILIPPINES SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 353 PHILIPPINES BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 354 PHILIPPINES SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 355 PHILIPPINES SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 356 PHILIPPINES PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 357 PHILIPPINES TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 358 PHILIPPINES SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 359 PHILIPPINES BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 360 PHILIPPINES SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 361 PHILIPPINES SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 362 PHILIPPINES GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 363 PHILIPPINES ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 364 PHILIPPINES SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 365 PHILIPPINES SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 366 PHILIPPINES RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 367 MALAYSIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 368 MALAYSIA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 369 MALAYSIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 370 MALAYSIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 371 MALAYSIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 372 MALAYSIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 373 MALAYSIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 374 MALAYSIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 375 MALAYSIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 376 MALAYSIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 377 MALAYSIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 378 MALAYSIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 379 MALAYSIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 380 MALAYSIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 381 MALAYSIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 382 MALAYSIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 383 MALAYSIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 384 MALAYSIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 385 MALAYSIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 386 MALAYSIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 387 MALAYSIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 388 MALAYSIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 389 MALAYSIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 390 MALAYSIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 391 MALAYSIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 392 MALAYSIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 393 MALAYSIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 394 MALAYSIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 395 MALAYSIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 396 MALAYSIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 397 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 398 NEW ZEALAND MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 399 NEW ZEALAND ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 400 NEW ZEALAND CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 401 NEW ZEALAND ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 402 NEW ZEALAND ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 403 NEW ZEALAND ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 404 NEW ZEALAND CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 405 NEW ZEALAND CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 406 NEW ZEALAND OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 407 NEW ZEALAND SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 408 NEW ZEALAND PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 409 NEW ZEALAND BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 410 NEW ZEALAND BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 411 NEW ZEALAND OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 412 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 413 NEW ZEALAND BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 414 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 415 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 416 NEW ZEALAND PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 417 NEW ZEALAND TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 418 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 419 NEW ZEALAND BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 420 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 421 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 422 NEW ZEALAND GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 423 NEW ZEALAND ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 424 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 425 NEW ZEALAND SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 426 NEW ZEALAND RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 427 VIETNAM SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 428 VIETNAM MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 429 VIETNAM ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 430 VIETNAM CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 431 VIETNAM ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 432 VIETNAM ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 433 VIETNAM ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 434 VIETNAM CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 435 VIETNAM CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 436 VIETNAM OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 437 VIETNAM SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 438 VIETNAM PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 439 VIETNAM BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 440 VIETNAM BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 441 VIETNAM OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 442 VIETNAM SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 443 VIETNAM BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 444 VIETNAM SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 445 VIETNAM SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 446 VIETNAM PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 447 VIETNAM TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 448 VIETNAM SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 449 VIETNAM BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 450 VIETNAM SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 451 VIETNAM SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 452 VIETNAM GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 453 VIETNAM ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 454 VIETNAM SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 455 VIETNAM SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 456 VIETNAM RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 457 TAIWAN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 458 TAIWAN MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 459 TAIWAN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 460 TAIWAN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 461 TAIWAN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 462 TAIWAN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 463 TAIWAN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 464 TAIWAN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 465 TAIWAN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 466 TAIWAN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 467 TAIWAN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 468 TAIWAN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 469 TAIWAN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 470 TAIWAN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 471 TAIWAN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
TABLE 472 TAIWAN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 473 TAIWAN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)
TABLE 474 TAIWAN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)
TABLE 475 TAIWAN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 476 TAIWAN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 477 TAIWAN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 478 TAIWAN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 479 TAIWAN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 480 TAIWAN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)
TABLE 481 TAIWAN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)
TABLE 482 TAIWAN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 483 TAIWAN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 484 TAIWAN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 485 TAIWAN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 486 TAIWAN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 487 REST OF ASIA-PACIFIC SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)
그림 목록
FIGURE 1 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN ARE EXPECTED TO DRIVE THE ASIA-PACIFIC SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD FROM 2023 TO 2030
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC SJS/TEN TREATMENT MARKET
FIGURE 14 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY TREATMENT, 2022
FIGURE 15 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY TREATMENT, 2023-2030 (USD MILLION)
FIGURE 16 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY TREATMENT, CAGR (2023-2030)
FIGURE 17 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2022
FIGURE 19 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)
FIGURE 20 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, CAGR (2023-2030)
FIGURE 21 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY CAUSE, 2022
FIGURE 23 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY CAUSE, 2023-2030 (USD MILLION)
FIGURE 24 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)
FIGURE 25 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY CAUSE, LIFELINE CURVE
FIGURE 26 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 27 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 28 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 29 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2022
FIGURE 31 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 32 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 33 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 34 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2022
FIGURE 35 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2023-2030 (USD MILLION)
FIGURE 36 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY THERAPY AREA, CAGR (2023-2030)
FIGURE 37 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY THERAPY AREA, LIFELINE CURVE
FIGURE 38 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2022
FIGURE 39 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)
FIGURE 40 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, CAGR (2023-2030)
FIGURE 41 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 42 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY END USER, 2022
FIGURE 43 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 44 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 45 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 46 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 47 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 48 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 49 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 50 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)
FIGURE 51 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)
FIGURE 52 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 53 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 54 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)
FIGURE 55 ASIA-PACIFIC SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
